Day: February 26, 2026

On February 25, 2026, the fund’s subsidiary EfTEN Ermi OÜ and Tartu Südamekodu OÜ reached an agreement on the expansion of the elderly care home located at Ermi tn 13, Tila village, Tartu municipality, Tartu County. As a result, 72 additional beds will be added.  The “Tartu Südamekodu” elderly care home, developed through the parties’ previous cooperation, has been providing services to clients since August 2024 and currently comprises 180 beds. By the end of last year, the facility had reached full occupancy.  It is planned to apply for a building permit for the construction of the extension in the second quarter of 2026 and then conduct a construction procurement, with the aim of completing the extension by June 2027. Tartu Südamekodu will then rent out the entire part of the building under construction. The estimated cost of the extension...

Highlights Record results withGroup turnover at 4.2 billion euros compared to 4.1 billion euros a year ago EBITDA at 931 million euros from 764 million euros a year ago, an increase of 22%, and reaching 22.4% of turnover, up from 18.6% for 2024 Net profit reaching 346 million euros, compared to 288 million euros a year ago, an increase of 20% Proposed gross dividend of 4.5 euros per share, compared to 3.8 euros per share a year agoOrder book stood at 7.6 billion euros at the end of the year, above both mid-year and 3Q25 levels and down from 8.2 billion euros a year ago Following the acquisition of Havfram, DEME has taken delivery of two next-generation offshore installation vessels, Norse Wind and Norse Energi, with project work commencing in 2026 DEME to celebrate its 150th anniversary in 2026Attachment...

Strong 2025 performance with renewedcommercial momentum at year-endRevenue up +10.3% in constant currencies, led by +14.4% growth in constant currencies of Planisware’s SaaS Model Commercial momentum improving and strong bookings with new logos at year-end Adjusted EBITDA margin* up +220bps to 37.4% of revenue reflecting operational discipline and scalability Profit for the period up +17.0% year-on-year to € 50.0 million or € 0.71 earnings per share Strong cash generation with adjusted FCF* reaching € 59.3 million (80.1% cash conversion), reinforcing the sound net cash position* reaching € 195.6 million € 0.36 proposed dividend per share, +16.1% year-on-year, representing a 50% pay-out 2026 objectives:Low double-digit revenue growth in constant currencies c. 37% Adjusted EBITDA margin1 c. 80% Cash Conversion Rate*Paris, France,...

Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MGResults support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMGRegulated Information – Inside Information  February 26, 2026, 6:30 AM CET    Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG). ADAPT OCULUS met its primary endpoint (p-value=0.012), showing that patients living...

Ad hoc announcement pursuant to Article 53 LR26 February 2026 – 06:30 AMThe Feintool Group’s business performance in the 2025 financial year reflects a market environment that remains challenging, with differing dynamics across regions and technologies. The global automotive market is growing at a low single-digit rate, while shifts in climate policy and subsidy schemes – particularly in the United States – are influencing investment decisions and the pace of electrification. At the same time, demand for industrial applications has remained subdued. Against this backdrop, Feintool has continued to align its cost structure consistently with prevailing market conditions, while maintaining a high degree of operational flexibility and a solid financial base. This enables the Group to remain a reliable and well-established partner for its customers,...

BEIJING, Feb. 26, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials. The Company completed patient enrollment of a Phase III registrational clinical trial of BCL2 inhibitor mesutoclax (ICP-248) in combination with BTK inhibitor orelabrutinib for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. Mesutoclax is a novel, highly selective oral BCL2 inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity...

New office strengthens global engineering capabilities to scale intelligent AI agents worldwide SANTA CLARA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) — SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice and conversational AI, today announced the opening of its new state-of-the-art innovation hub in Bengaluru, India. The expansion marks a significant milestone in the company’s evolution to scale agentic AI globally, positioning SoundHound at the epicenter of India’s rapidly accelerating AI economy. The opening coincides with a period of historic momentum for the Indian technology sector. As the country reinforces its role as a global AI powerhouse, SoundHound’s new Bengaluru hub will serve as a critical engine for the company’s next wave of innovation, including continued advancement of its next generation agentic AI platform. SoundHound...